SCHEMBL25353722

SCHEMBL25353722

O=C1Nc2ccc(Br)cc2C(=O)N2CCN(Cc3ccc4c(c3)OCO4)CC12

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.55
▸ ALDH3A1 P30838 2/20 0.55
▸ KMT2A Q03164 3/20 0.44
▸ MAPT P10636 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ HTT P42858 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ CMA1 P23946 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ CASP7 P55210 1/20 0.41
▸ MCHR1 Q99705 3/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25354038 0.81 IKZF2 (0.43) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL25353734 0.81 NOTUM (0.47) —
SCHEMBL30517878 0.79 CHRM3 (0.42) ALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL25353201 0.79 CHRM3 (0.42) ALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL30517888 0.78 MEN1 (0.37) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL25353872 0.78 MEN1 (0.37) ALDH1A1KMT2AMAPTMEN1KDM4E
Trifluoroacetic Acid SCHEMBL30517844 0.78 S1PR5 (0.45) ALDH1A1ALDH3A1KMT2AMEN1HTT
SCHEMBL25352010 0.77 PLK4 (0.41) ALDH1A1KMT2AMEN1KDM4ETDP1
SCHEMBL25998333 0.74 MEN1 (0.50) KMT2AMEN1
SCHEMBL25353999 0.74 MEN1 (0.39) ALDH1A1KMT2AMAPTMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250134907-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-05-01 — — US disclosed
EP-4476222-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2024-12-18 — — EP disclosed
WO-2023154197-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-08-17 — — WO disclosed
WO-2023154197-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250134907-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF RXFP3, RXFP4, RXFP2 ALDH1A1 4818/4885ALDH3A1 4388/4885KMT2A 3199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback